<p>NRx Pharmaceuticals（納斯達克代碼：NRXP - 獲取免費報告）於週五公佈了季度財報。公司報告的每股收益為（$0.18），低於分析師一致預期的（$0.11），差距為（$0.07），據 Zacks 報道。公司本季度的收入為 24 萬美元，而分析師預期為 683 萬美元。</p>
<p>獲取 <strong>NRx Pharmaceuticals</strong> 警報：</p>
<h2>NRx Pharmaceuticals 股票下跌 3.9%</h2>
<p>週五，納斯達克：NRXP 的股票交易下跌 0.10 美元，報 2.49 美元。該股票的交易量為 432,261 股，而其平均交易量為 475,505 股。NRx Pharmaceuticals 的 12 個月低點為 1.13 美元，12 個月高點為 6.01 美元。該股票的 50 日簡單移動平均為 3.02 美元，200 日簡單移動平均為 2.87 美元。該股票的市值為 4933 萬美元，市盈率為-1.11，貝塔值為 1.76。</p>
<h2>機構投資者對 NRx Pharmaceuticals 的看法</h2>
<p>對沖基金最近買賣了該股票的股份。Two Sigma Investments LP 在第三季度將其在 NRx Pharmaceuticals 的持倉增加了 66.4%。Two Sigma Investments LP 現在擁有 52,332 股該公司的股票，價值 173,000 美元，此前在該期間內增持了 20,880 股。Geode Capital Management LLC 在第二季度將其在 NRx Pharmaceuticals 的股份增加了 27.9%。Geode Capital Management LLC 現在擁有 172,255 股該公司的股票，價值 562,000 美元，此前在上個季度增持了 37,598 股。最後，Vanguard Group Inc.在第三季度將其在 NRx Pharmaceuticals 的股份增加了 18.3%。Vanguard Group Inc.現在擁有 534,956 股該公司的股票，價值 1,765,000 美元，此前在上個季度增持了 82,781 股。對沖基金和其他機構投資者持有該公司 4.27% 的股份。</p>
<h2>分析師評級上調和下調</h2>
<p>一些股票分析師最近對 NRXP 股票發表了評論。Weiss Ratings 在 10 月 8 日的報告中重申了對 NRx Pharmaceuticals 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 16 日的報告中重申了 “買入” 評級，並對 NRx Pharmaceuticals 股票設定了 40.00 美元的目標價。Wall Street Zen 在週六的報告中將 NRx Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Ascendiant Capital Markets 在 10 月 30 日的研究報告中將 NRx Pharmaceuticals 的股票目標價從 46.00 美元上調至 47.00 美元，並給予該公司 “買入” 評級。最後，D. Boral Capital 在 11 月 10 日的研究報告中重申了 “買入” 評級，並對 NRx Pharmaceuticals 的股票設定了 34.00 美元的目標價。四位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 34.75 美元。</p>
<p><strong>查看我們對 NRXP 的最新分析</strong></p>
<h2>關於 NRx Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>NRx Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，開發用於治療中樞神經系統疾病的新型療法，包括自殺性抑鬱症、創傷後應激障礙和慢性疼痛。其產品包括 NRX-101（D-環絲氨酸/盧拉西酮），這是一種口服固定劑量的 D-環絲氨酸和盧拉西酮的組合，獲得了食品和藥物管理局指定的自殺治療耐藥性雙相抑鬱症的突破性療法；以及 NRX-100（氯胺酮），該藥物已獲得 FDA 快速通道認證，用於治療伴有急性自殺意念和行為的重度雙相抑鬱症。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 NRx Pharmaceuticals</li>
<li>交易暫停的解釋</li>
<li>3 只低調的 AI 股票，值得在下跌時購買</li>
<li>什麼是日經 225 指數？</li>
<li>你的感恩節投資計劃：3 只將受益於足球熱潮的股票</li>
<li>3 只值得長期持有的 REITs</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA"/></p>
<h2>你現在應該投資 NRx Pharmaceuticals 1000 美元嗎？</h2>
<p>在你考慮 NRx Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NRx Pharmaceuticals 並不在名單上。</p>
<p>雖然 NRx Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NRXP

<p>NRx Pharmaceuticals（納斯達克代碼：NRXP）報告了每股虧損 0.18 美元，低於市場普遍預期的 0.08 美元。該公司的收入為 24 萬美元，低於預期的 683 萬美元。股價下跌 3.9%，至 2.49 美元。機構投資者增加了持股，分析師的評級意見不一，市場共識目標價為 34.75 美元。NRx 專注於開發中樞神經系統疾病的治療方案</p>

<p>NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.07), Zacks reports. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $6.83 million.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals（納斯達克代碼：NRXP - 獲取免費報告）於週五公佈了季度財報。公司報告的每股收益為（$0.18），低於分析師一致預期的（$0.11），差距為（$0.07），據 Zacks 報道。公司本季度的收入為 24 萬美元，而分析師預期為 683 萬美元。</p>
</div><p>Get <strong>NRx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>NRx Pharmaceuticals</strong> 警報：</p>
</div><h2>NRx Pharmaceuticals Stock Down 3.9%</h2>
<div class="lb-trans"><h2>NRx Pharmaceuticals 股票下跌 3.9%</h2>
</div><p>Shares of NASDAQ:NRXP traded down $0.10 during trading on Friday, hitting $2.49. The stock had a trading volume of 432,261 shares, compared to its average volume of 475,505. NRx Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $6.01. The stock has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $2.87. The stock has a market capitalization of $49.33 million, a price-to-earnings ratio of -1.11 and a beta of 1.76.</p>
<div class="lb-trans"><p>週五，納斯達克：NRXP 的股票交易下跌 0.10 美元，報 2.49 美元。該股票的交易量為 432,261 股，而其平均交易量為 475,505 股。NRx Pharmaceuticals 的 12 個月低點為 1.13 美元，12 個月高點為 6.01 美元。該股票的 50 日簡單移動平均為 3.02 美元，200 日簡單移動平均為 2.87 美元。該股票的市值為 4933 萬美元，市盈率為-1.11，貝塔值為 1.76。</p>
</div><h2>Institutional Investors Weigh In On NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 NRx Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after acquiring an additional 20,880 shares during the period. Geode Capital Management LLC raised its position in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近買賣了該股票的股份。Two Sigma Investments LP 在第三季度將其在 NRx Pharmaceuticals 的持倉增加了 66.4%。Two Sigma Investments LP 現在擁有 52,332 股該公司的股票，價值 173,000 美元，此前在該期間內增持了 20,880 股。Geode Capital Management LLC 在第二季度將其在 NRx Pharmaceuticals 的股份增加了 27.9%。Geode Capital Management LLC 現在擁有 172,255 股該公司的股票，價值 562,000 美元，此前在上個季度增持了 37,598 股。最後，Vanguard Group Inc.在第三季度將其在 NRx Pharmaceuticals 的股份增加了 18.3%。Vanguard Group Inc.現在擁有 534,956 股該公司的股票，價值 1,765,000 美元，此前在上個季度增持了 82,781 股。對沖基金和其他機構投資者持有該公司 4.27% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>A number of equities analysts recently commented on NRXP shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright restated a &#34;buy&#34; rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 30th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.75.</p>
<div class="lb-trans"><p>一些股票分析師最近對 NRXP 股票發表了評論。Weiss Ratings 在 10 月 8 日的報告中重申了對 NRx Pharmaceuticals 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 16 日的報告中重申了 “買入” 評級，並對 NRx Pharmaceuticals 股票設定了 40.00 美元的目標價。Wall Street Zen 在週六的報告中將 NRx Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Ascendiant Capital Markets 在 10 月 30 日的研究報告中將 NRx Pharmaceuticals 的股票目標價從 46.00 美元上調至 47.00 美元，並給予該公司 “買入” 評級。最後，D. Boral Capital 在 11 月 10 日的研究報告中重申了 “買入” 評級，並對 NRx Pharmaceuticals 的股票設定了 34.00 美元的目標價。四位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，共識目標價為 34.75 美元。</p>
</div><p><strong>View Our Latest Analysis on NRXP</strong></p>
<div class="lb-trans"><p><strong>查看我們對 NRXP 的最新分析</strong></p>
</div><h2>About NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 NRx Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，開發用於治療中樞神經系統疾病的新型療法，包括自殺性抑鬱症、創傷後應激障礙和慢性疼痛。其產品包括 NRX-101（D-環絲氨酸/盧拉西酮），這是一種口服固定劑量的 D-環絲氨酸和盧拉西酮的組合，獲得了食品和藥物管理局指定的自殺治療耐藥性雙相抑鬱症的突破性療法；以及 NRX-100（氯胺酮），該藥物已獲得 FDA 快速通道認證，用於治療伴有急性自殺意念和行為的重度雙相抑鬱症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than NRx Pharmaceuticals</li>
<li>Trading Halts Explained</li>
<li>3 Under-the-Radar AI Stocks to Buy on the Dip</li>
<li>What is the Nikkei 225 index?</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 NRx Pharmaceuticals</li>
<li>交易暫停的解釋</li>
<li>3 只低調的 AI 股票，值得在下跌時購買</li>
<li>什麼是日經 225 指數？</li>
<li>你的感恩節投資計劃：3 只將受益於足球熱潮的股票</li>
<li>3 只值得長期持有的 REITs</li>
<li>MarketBeat 週迴顧 – 11/10 - 11/14</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NRXP"/></p>
<h2>Should You Invest $1,000 in NRx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 NRx Pharmaceuticals 1000 美元嗎？</h2>
</div><p>Before you consider NRx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 NRx Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 NRx Pharmaceuticals 並不在名單上。</p>
</div><p>While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 NRx Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NRx Pharmaceuticals（NASDAQ:NRXP）公佈財報結果